Milestones

  • Licensed first in class dual IDO/TDO inhibitors patents
    to Roche

  • Developed and sold strategy for dual kinase inhibition
    to US pharma

  • Selected by London Partners as one of “India’s Emerging
    20” companies

  • Six patents filed

  • Two posters presented at AACR

Key Events

Under its CSR program, Curadev sponsored Impact India’s 172nd Lifeline Express (World’s First Hospital Train) project at Gondia in Maharashtra from May 4 to 25, 2016. The aim of the Lifeline Express is to deliver quality medical and surgical services in rural and remote areas of our country.

About curadev

Curadev was created in 2010 by a team of professionals motivated to improve human health and enhance the quality of life by
discovering new drugs. Curadev is part of the biotech wave that has captured the shift to asset creation by agile and empowered teams in
the drug discovery business world.

Approach

Drug discovery starts with insightful target selection. Often target selection is a more critical driver of success than selecting the “optimal” therapeutic area. Our selection of drug targets is curated from peer-reviewed literature after an extensive analysis using defined metrics to identify targets ripe for translation. Our size and structure encourage independent thinking and our drive for quantitative rigor in analysis make us optimally suited to execute swiftly on drug discovery projects.

From an operational standpoint, our leadership is empowered to work on parallel approaches and encouraged to take decisions. We minimize cumbersome internal processes that delay advancement of projects and stress optimal experimentation and analytical thinking.

THIS HAS ALLOWED CURADEV TO GENERATE INTELLECTUAL
PROPERTY IN A RELATIVELY SHORT TIME FRAME.

OUR TEAM

Curadev attracts passionate, creative people and builds extraordinarily productive teams. Through a careful recruiting process, Curadev has built a well-knit team of scientific investigators who thrive on the constant challenges of drug discovery research.

Arjun Surya

Chief Scientific Officer

View Profile

Manish Tandon

Chief Financial Officer

View Profile

Sourav Basu

Vice President, R&D

View Profile

Monali Banerjee

Director, R&D

View Profile

David Pryde

Director R&D

View Profile

Curadev has a world-class scientific advisory board that works in close association with Curadev scientists to identify new research directions and accelerate Curadev’s target validation and drug discovery programs.


Dr. Richard M. Keenan

View Profile

Dr. Robert McBurney

View Profile

Dr. Eliot H. Ohlstein

View Profile

Dr. Stephen R. Wicks

View Profile

science

Novel Drugs

Curadev focuses on the creation and out-licensing of pre-IND assets and IND packages for drug development. We take a literature driven approach to identify drug targets, which are then validated in house. We consider gene knockout information, human genetic association and various types of pre-clinical data that speak to the expression and function of the target to build a model of its role in disease. An ‘out of the box’ approach to drug design helps us to rapidly establish a medchem program.

Research Interests

  • Kynurenine Pathway Inhibition: Greater than 90% of ingested tryptophan is metabolized through the kynurenine pathway by the heme containing oxidoreductase enzymes indoleamine 2,3 dioxygenase (IDO) and tryptophan 2,3 dioxygenase (TDO). High levels of these enzymes and metabolites of tryptophan are associated with a variety of human pathologies that include various kinds of cancer, Alzheimer’s Disease, Schizophrenia and in infectious diseases that include HIV and malaria. Inhibiting these enzymes in a variety of pre-clinical models leads to favorable outcomes. Curadev has developed potent small molecules inhibitors (Patents filed) that reduce kynurenine levels in a range of experimental paradigms. The inhibitors all into two classes – IDO specific inhibitors and IDO/TDO dual inhibitors. The therapeutic goal is to combine these molecules with other immune check point inhibitors against CTLA4, PD-L1/PD1 or LAG3 to potentiate the immune response against various types of tumors.
  • Interface between innate and adaptive immunity in cancer
  • Dysregulated tumor metabolism
AACR (2014) Tumor Immunology and Immunotherapy: A New Chapter
View
AACR (2016) Annual Meeting
View

latest news


Senior Representatives of
Curadev will be available at:

Date: June 2016

READ MORE

Dr. David Cameron Pryde
appointed Director, R&D of
Curadev UK

Date: April 2016

READ MORE

American Association for
Cancer Research meeting in
New Orleans

Date: April 2016

READ MORE

Contact us


Curadev Pharma Private Limited


B 87, Sector 83 Noida, UP 201305 INDIA
Tel: +91-120-408 1818/19
Fax: +91-120-408 1820

EMAIL:
For Investment, Partnering & Collaboration enquiries: business@curadev.in
For all other enquiries: interact@curadev.in